1
|
Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcaïs A, Malloci M, Fanton d’Andon M, Beauvais T, Labarriere N, Jeannin P, Abel L, Saint-André JP, Croué A, Delneste Y, Boneca IG, Marsollier L, Marion E. Mycolactone toxin induces an inflammatory response by targeting the IL-1β pathway: Mechanistic insight into Buruli ulcer pathophysiology. PLoS Pathog 2020; 16:e1009107. [PMID: 33338061 PMCID: PMC7748131 DOI: 10.1371/journal.ppat.1009107] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Accepted: 10/29/2020] [Indexed: 12/12/2022] Open
Abstract
Mycolactone, a lipid-like toxin, is the major virulence factor of Mycobacterium ulcerans, the etiological agent of Buruli ulcer. Its involvement in lesion development has been widely described in early stages of the disease, through its cytotoxic and immunosuppressive activities, but less is known about later stages. Here, we revisit the role of mycolactone in disease outcome and provide the first demonstration of the pro-inflammatory potential of this toxin. We found that the mycolactone-containing mycobacterial extracellular vesicles produced by M. ulcerans induced the production of IL-1β, a potent pro-inflammatory cytokine, in a TLR2-dependent manner, targeting NLRP3/1 inflammasomes. We show our data to be relevant in a physiological context. The in vivo injection of these mycolactone-containing vesicles induced a strong local inflammatory response and tissue damage, which were prevented by corticosteroids. Finally, several soluble pro-inflammatory factors, including IL-1β, were detected in infected tissues from mice and Buruli ulcer patients. Our results revisit Buruli ulcer pathophysiology by providing new insight, thus paving the way for the development of new therapeutic strategies taking the pro-inflammatory potential of mycolactone into account. Buruli ulcer is a neglected tropical disease occurring mainly in poor rural areas of West and Central Africa. This cutaneous disease is caused by Mycobacterium ulcerans, a bacterium belonging to the same family as M. tuberculosis and M. leprae. The skin lesions are caused by a cytotoxic toxin named mycolactone, also known to act as an immunosuppressor and an anti-inflammatory molecule. However, Buruli ulcer lesions are characterized by a chronic cutaneous inflammation with a recruitment of cellular immune cells trying to counteract M. ulcerans. Our work allows for a reconcilitation of previous observations. We found by in vitro experiment on macrophages that the mycolactone-containing mycobacterial extracellular vesicles produced by M. ulcerans induced the production of IL-1β, a potent pro-inflammatory molecule, while other pro-inflammatory soluble factors are inhibited. We also detected IL-1β protein in a mouse model of M. ulcerans infection as well as in biopsies of Buruli ulcer patients. The pro-inflammatory potential of mycolacone has to be taken into account to understand the full pathophysiology of Buruli ulcer.
Collapse
Affiliation(s)
- M. Foulon
- Université d’Angers, INSERM, CRCINA, Angers, France
| | | | - J. Manry
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Paris, France
- Université de Paris, Imagine Institute, France
| | - L. Esnault
- Université d’Angers, INSERM, CRCINA, Angers, France
| | - Y. Boucaud
- Université d’Angers, INSERM, CRCINA, Angers, France
| | - A. Alcaïs
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Paris, France
- Université de Paris, Imagine Institute, France
| | - M. Malloci
- Plateforme MicroPiCell, SFR santé François Bonamy, Nantes, France
| | - M. Fanton d’Andon
- Institut Pasteur, Unité Biologie et Génétique de la Paroi Bactérienne, Paris, France; CNRS, INSERM, Équipe Avenir, Paris, France
| | - T. Beauvais
- Université de Nantes, INSERM, CRCINA, Nantes
| | | | - P. Jeannin
- Université d’Angers, INSERM, CRCINA, Angers, France
- Laboratoire d’Immunologie et Allergologie, CHU Angers, Angers, France
| | - L. Abel
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Paris, France
- Université de Paris, Imagine Institute, France
| | - J. P. Saint-André
- Département de Pathologie Cellulaire et Tissulaire, CHU Angers, Angers, France
| | - A. Croué
- Département de Pathologie Cellulaire et Tissulaire, CHU Angers, Angers, France
| | - Y. Delneste
- Université d’Angers, INSERM, CRCINA, Angers, France
- Laboratoire d’Immunologie et Allergologie, CHU Angers, Angers, France
| | - I. G. Boneca
- Institut Pasteur, Unité Biologie et Génétique de la Paroi Bactérienne, Paris, France; CNRS, INSERM, Équipe Avenir, Paris, France
| | | | - E. Marion
- Université d’Angers, INSERM, CRCINA, Angers, France
- * E-mail:
| |
Collapse
|